Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2-positive metastatic breast cancer. It consists of trastuzumab, a humanized monoclonal antibody directed against human epidermal growth factor receptor 2 (HER2) and a microtubule inhibitor DM1 conjugated to trastuzumab via a thioether linker. Hepatotoxicity is one of the serious adverse events associated with T-DM1 therapy. Mechanisms underlying T-DM1-induced hepatotoxicity remain elusive. Here, we use hepatocytes and mouse as models to investigate the mechanisms of T-DM1-induced hepatotoxicity. We show that T-DM1 is internalized upon binding to cell surface HER2 and is co-localized with LAMP1, resulting in DM1-associated cytotoxicity, including disorganized microtubules, nuclear fragmentation/multiple nuclei, and cell growth inhibition. We further demonstrate that T-DM1 treatment significantly increases the serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) in mice, and induces inflammation and necrosis in liver tissues and that T-DM1-induced hepatotoxicity is dose dependent. Moreover, the gene expression of TNFα in liver tissues is significantly increased in mice treated with T-DM1 as compared with that treated with trastuzumab or vehicle. We propose that T-DM1-induced upregulation of TNFα enhances the liver injury that may be initially caused by DM1-mediated intracellular damage. Our proposal is underscored by the fact that T-DM1 induces the outer mitochondrial membrane rupture, a typical morphological change in the mitochondrial-dependent apoptosis, and mitochondrial membrane potential dysfunction. Our work provides mechanistic insights into T-DM1-induced hepatotoxicity, which may yield novel strategies to manage liver injury induced by T-DM1 or other ADCs.
Introduction
Antibody-drug conjugates (ADCs) are an emerging group of therapeutic agents that are generated by covalent attachment of cytotoxic agents to monoclonal antibodies via linkers (1) .
They are designed to selectively deliver cytotoxic agents to tumor cells where specific tumorassociated antigens are overexpressed on the cell surface, thereby minimizing systemic toxicity.
Ado-trastuzumab emtansine (also known as T-DM1) is an antibody-drug conjugate (ADC) approved by the U.S. Food and Drug Administration for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in patients previously treated with trastuzumab and taxane (2) . T-DM1 consists of trastuzumab, a humanized monoclonal antibody directed against HER2 and a microtubule inhibitor DM1 that is conjugated to trastuzumab via a thioether linker (3) . DM1 is a potent microtubule polymerization inhibitor that induces mitotic arrest and kills tumor cells at sub-nanomolar concentration (4) . It is 25-to 270-fold more potent than paclitaxel and 180-to 4,000-fold more potent than doxorubicin (5, 6) . However, its side effects and lack of specificity prevented it from clinical use (7).
HER2 is a member of EGFR/ErbB family of receptor tyrosine kinases with significant roles in breast cancer tumorigenesis and is overexpressed in 15-30% of breast cancers (8) . Upon binding to HER2, T-DM1 is internalized and processed in lysosomes to release the active catabolite lysine-N(ε)-N-maleimidomethyl-cyclohexane-1-carboxylate (MCC)-DM1 (Lys-MCC-DM1) (3, (9) (10) (11) (12) . The released Lys-MCC-DM1 exerts anti-microtubule functions via microtubule destabilization which results in mitotic arrest, cell growth inhibition, and cell death (9) (10) (11) (12) . T-DM1 significantly prolongs progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer (13, 14) .
However, T-DM1 therapy is associated with serious grade 3 or greater adverse events, including hepatotoxicity (13) (14) (15) . It was reported that all-grade increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) occurred in 208 (23.5%) and 139 (15.7%) patients, respectively out of 884 T-DM1-exposed patients. 36 patients (4.1%) had grade 3 increase in serum ALT (4.1%), 2 patients (0.2%) grade 4 increase in serum ALT, and 27 patients (3.1%) grade 3 increase in serum AST (15) . Three patients were diagnosed with nodular regenerative hyperplasia (NRH), which resulted in one death due to liver failure. Hepatotoxicity is one of black box warnings on the labeling for the prescription of T-DM1
(http://www.gene.com/download/pdf/kadcyla_prescribing.pdf). However, mechanisms underlying T-DM1-induced hepatotoxicity remain elusive (15) . It has not been reported whether T-DM1 directly targets hepatocytes via HER2 to induce hepatotoxicity.
Gemtuzumab ozogamicine (GO) is an ADC consisting of an anti-CD33 monoclonal antibody conjugated to calicheamicin (16) . GO was approved in 2000 for the treatment of acute myeloid leukemia (AML) and was withdrawn from the market in 2010 due to product safety and efficacy concerns (17, 18) . Among the safety concerns were clinical symptoms of hepatotoxicity, including hepatic veno-occlusive disease, which is a significant GO related toxicity (19) . In addition, 29% of patients had Grade 3 or Grade 4 hyperbilirubinemia and 9% had Grade 3 or Grade 4 ALT level abnormalities (20) . However, the cause of GO-induced hepatotoxicity remains unproven. Study by Maniecki et al. demonstrated that CD33 receptor, thought to be a specific marker for the cells of the myeloid lineage, is widely distributed in the liver tissue and highly 6 expressed on hepatocytes (21) . This study suggested that the specific targeting of hepatocytes by GO resulted in the accumulation of antibody-toxin conjugates in hepatocytes causing calicheamicin-induced damage (20) . Besides GO, signs of liver dysfunction were also identified in other ADC therapies in clinical testing (22) (23) (24) . Given the significant clinical potential of ADC therapies and the substantial increase in number of ADCs in clinical trials, it is critical to obtain a better understanding of mechanisms by which ADCs, including T-DM1, induce hepatotoxicity.
Murine model has been widely used to study the mechanisms of trastuzumab-induced cardiotoxicity (25-29). Riccio et al have shown that trastuzumab binds to mouse HER2 (26) and that mice treated with trastuzumab have reduced left ventricular ejection fraction (LVEF) (25-29). Trastuzumab may directly block anti-apoptotic signaling, leading to premature cardiac dysfunction (28). Although HER2 is present at a low level in mouse cardiomyocytes, the studies from different laboratories suggested that trastuzumab-induced cardiotoxicity may be HER2-dependent (25-29). Furthermore, trastuzumab treatment induces apoptosis in cardiac sections of heart tissues from mice treated with trastuzumab (25, 28). In this study, we used the cellular and murine models to investigate the mechanisms by which T-DM1 induces hepatotoxicity. We aimed to evaluate HER2 expression in mouse and human hepatocytes and T-DM1-induced endocytosis. We also examined its associated intracellular damage, and liver injury in mice treated with T-DM1. Human hepatocytes (THLE2) and mouse hepatocytes (AML12) were obtained from ATCC and used within six months after cell lines were ordered and cultured in BEGM SingleQuots medium containing 10% fetal bovine serum (FBS) and DMEM/F-12 (1:1) mixture containing 10% FBS, respectively. Human primary hepatocytes (HPH) were obtained from ScienCell and used within the six months after the cells were ordered. THLE2, AML12 and HPH were not authenticated in our laboratory. αHFc-NC-DM1 is anti-human IgG Fc specific antibody conjugated to maytansinoid DM1 with a non-cleavable linker. αMFc-NC-DM1 is anti-mouse IgG Fc specific antibody conjugated to maytansinoid DM1 with a non-cleavable linker. Both HFc-NC-DM1 and MFc-NC-DM1 were purchased from Moradec LLC.
Materials and Methods

Cell lines and control DM1 ADC
Immunofluorescence microscopy
For LAMP1 and microtubule-staining, cells were plated on fibronectin (10 µg/ml, SigmaAldrich) pre-coated glass coverslips (12 mm; Fisher Scientific) in 12-well plate (Corning) and cultured overnight. After washing with pre-warmed DPBS twice, cells were fixed in 4% paraformaldehyde (PFA, Electron Microscopy Sciences) in DPBS for 15 min and permeabilized with 0.2% Triton X-100 in DPBS for 10 min. The samples were washed with DPBS and blocked with 2% bovine serum albumin (BSA) in DPBS at room temperature for 1-2 hours. Anti-α-tubulin (clone DM1A, Sigma-Aldrich) or anti-LAMP1 (BD Biosciences) antibodies were diluted 1:100 in the blocking solution, and the samples were incubated with these antibodies at 4 o C overnight. After washing with DPBS three times, the samples were incubated with Alexa Fluor 488 or 594- 
Immunohistochemistry (IHC)
Livers from healthy C57BL/6 mice were harvested, fixed and embedded in paraffin. 
Duolink proximity ligation assay
Duolink proximity ligation assay (PLA) was performed according to the instructions obtained from the manufacturer's website (http://www.olink.com/products/duolink/downloads/duolinkmanuals-and-guidelines). Briefly, the cells were fixed and permeabilized and incubated with primary antibodies from two different species recognizing either C-terminal region of HER2 (rabbit polyclonal) or DM1 component of T-DM1 (mouse monoclonal). As a control, cells that were not treated with T-DM1, but stained for HER2 and DM1, were used. Controls also included no primary antibodies. After washing and permeabilization step, the cells were incubated with secondary antibodies with the ligated oligonucleotide probes (PLA plus and PLA minus) for 1 hour at 37 
Serum hepatic markers
Blood collection and serum isolation: Tail vein nick was performed during survival blood collection, and terminal cardiac blood collection was used during euthanasia. ALT, AST and LDH serum test was conducted in the chemistry laboratory at NIH clinical center using the same produces as those used for human clinical samples. Total RNA was isolated from freshly frozen liver tissues and reverse transcriptase Superscript II (Life Technologies) was used for cDNA synthesis according to the manufacturer's protocol. Quantitative PCR was performed using Taqman Gene Expression PCR Master Mix and commercially available primers for genes with the 7900 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA). Actin was used as reference to normalize the expression level.
Reverse transcription and quantitative PCR
Electron Microscope
Fresh liver samples were fixed for 1 hour at room temperature and then overnight at 4°C in TEM/SEM tousimis® Glutaraldehyde, 2.5% in 0.1M Na-Cacodylate Buffer (Tousimis, Rockville MD), osmicated for 1 hour at the room temperature in the same buffer, en bloc stained with 0.5% uranyl acetate for 1 hour, dehydrated in a graded ethanol series, embedded in Epon 812 substitute, and examined on a Hitachi H7650 transmission electron microscope.
Mitochondria membrane potential assay
Cells were plated on fibronectin pre-coated glass coverslips in 12-well plate and cultured overnight. Next day cells were treated with T-DM1 (0 or 20 µg/ml) and then incubated for 2 days.
Mitochondrial Transmembrane Potential Apoptosis Detection Kit (Abcam) was used according to the manufacturer's protocol. Images were captured by EVOS FL system (Life Technologies).
According to the manufacturer's instructions, the kit utilizes a cationic dye that fluoresces differently in healthy vs. apoptotic cells. In healthy cells, the dye accumulates and aggregates in the mitochondria with bright fluorescence, whereas in apoptotic cells, the dye cannot aggregate in mitochondria due to the altered mitochondrial transmembrane potential. Alexa Fluor 488 Protein Labeling Kit (Life Technologies) was used for the labeling of T-DM1 with Alexa Fluor 488. Briefly, 2.5 mg T-DM1 (5 mg/ml, 0.5 ml in DPBS) was conjugated with Alexa Fluor 488 according to the manufacturer's instructions. The kit has a tetrafluorophenyl (TFP) ester moiety, and it reacts efficiently with primary amines of T-DM1 to form stable dyeprotein conjugate. The Alexa Fluor 488-labeled T-DM1 was eluted by serum-free BEGM medium.
Alexa Fluor 488-conjugation
Western Blotting and Immunoprecipitation
Whole cell lysates (WCL) of THLE2 or AML12 cells were used either for detection of HER2 protein expression or immunoprecipitation experiments. For immunoprecipitation, WCL were incubated with control IgG (human IgG, Life Technologies), trastuzumab, T-DM1 or anti-HER2 antibody (29D8, Cell Signaling Technology). The immuneprecipitated HER2 was detected using anti-HER2 antibody (29D8), which recognizes both mouse and human HER2.
Statistical analysis
GraphPad Prism was used for statistical studies. Statistical significance was determined by Student's t-test (*, P < 0.05; **, P < 0.01). Data are expressed as mean ± SEM.
Results
HER2 is expressed in mouse and human hepatocytes, and T-DM1 associates with HER2 on the hepatocyte cell surface
To investigate the possibility that specific targeting of hepatocytes via HER2 may www.proteinatlas.org).
We next examined the interaction of trastuzumab or T-DM1 with HER2 in hepatocytes. As shown in Figure 1F (arrowheads), the strong positive signal was detected at the cell edges of both human and mouse hepatocytes when either trastuzumab or T-DM1 was used for detection of cell surface HER2, suggesting that both trastuzumab and T-DM1 bind to HER2 expressed on the cell surface. In contrast, control IgG did not give rise to any positive signal on the cell surface ( Figure   1F ). Using Duolink proximity ligation assay (PLA), we further confirmed that T-DM1 bound to HER2 expressed in hepatocytes ( Figure 1G ). 
was capable of destabilizing microtubule structures (white arrow), inducing multi-nuclei in mouse hepatocytes (red arrows), and inhibiting AML12 cell growth ( Figure 2C, graph) . Furthermore, as shown in Figure 2D and E, the ability to inhibit THLE2 cell growth by non-HER2 targeting control ADCs (αHFc-NC-DM1 and αMFc-NC-DM1) was significantly reduced as compared to T-DM1, indicating that the T-DM1-induced cytotoxicity is mainly HER2-dependent in this in vitro toxicology study. Taken together, these data suggest that T-DM1 can specifically target both human and mouse hepatocytes via HER2, resulting in DM1-associated intracellular damages. Figure 3D ). We observed a downward trend in the serum levels of TNFα from Day 1 to Day 7 ( Figure 3D ).
T-DM1 treatment increases
We next addressed whether T-DM1 induced the elevation of serum ALT, AST and LDH in a dose dependent manner. As shown in Figure 3E , the significant increases in serum levels of ALT and AST, but not LDH, were observed in mice treated with the highest dose of T-DM1 (30 mg/kg) at the 12h post T-DM1 injection. At 72h post-treatment of T-DM1, the serum levels of ALT, AST and LDH were significantly increased at the dose of 30 mg/kg of T-DM1 ( Figure 3F) , consistent with data shown in Figure 3B . The serum levels of ALT and LDH, but not AST, were also significantly increased at the dose of 10 mg/kg of T-DM1, and there were no significant increases in ALT, AST and LDH at the dose of 3 mg/kg of T-DM1 ( Figure 3F ). These data indicated that T-DM1-induced liver injure was in a dose dependent manner. Surprisingly, the serum levels of ALT were also increased in mice treated with trastuzumab at 72h post-injection as compared with control mice (Figure 3F ).
T-DM1 treatment induces inflammation and necrosis in liver tissues
The hallmarks of acute hepatocellular injury are inflammation and/or necrosis (34) . Both inflammation (green arrows) and necrosis (yellow arrows) were found in liver tissues from the (Table 1B) . No necrosis was found in liver tissues obtained from the mice treated with vehicle control or trastuzumab (Table 1B) .
T-DM1 induces the outer mitochondrial membrane rupture and mitochondrial membrane potential dysfunction
The outer mitochondrial membrane rupture (OMR), which releases mitochondrial proteins of the intermembrane space into the cytoplasm, has been implicated as the central event of the mitochondrial-dependent apoptosis (35) . These mitochondrial proteins initiate and execute the apoptotic processes (35) . Electron microscopy (EM) study demonstrated that outer mitochondrial membrane rupture was frequently observed in T-DM1-treated liver cells, while control and trastuzumab-treated liver cells showed no damages in cell organelle structures ( Figure 5A , red arrows). To confirm the observation from the mice, we also examined whether mitochondrial dysfunction could be found in hepatocytes treated with T-DM1. As shown in 
Discussion
Hepatotoxicity is widely regarded as the leading cause of failure of drug development programs and a serious safety concern in clinical studies and post-marketing surveillance (36, 37) . In the analysis of drugs withdrawn for toxicity reasons in the period between 1992 and 2002, hepatotoxicity was identified in 27% of cases (36) . While mechanisms underlying most instances of drug-induced hepatotoxicity are still not well understood, different studies implicated factors such as host metabolism, detoxification, liver-regeneration and immune response pathways (38, 39) .
Hepatotoxicity has been reported in several other ADC therapies currently undergoing different stages of clinical testing (22) (23) (24) . In a phase 1 study of cantuzumab mertansine, hepatotoxicity (reversible elevations of hepatic transaminases and occasionally alkaline phosphatase and bilirubin) were identified as principal toxic side effects of the therapy (22) . In a phase I study of inotuzumab ozogamicine, increased aspartate aminotransferases and bilirubinemia were reported for 18.4% and 22.4% of study participants, respectively (23). In a phase 1 study of MLN2704, which is an ADC designed to deliver DM1 to prostate-specific Thrombocytopenia is the dose-limiting toxicity induced by T-DM1 (13, 40) . A study conducted by Uppal et al. suggests that human megakaryocytes (MKs) internalize T-DM1 in a HER2-independent, FcγRIIa-dependent manner, resulting in intracellular release of DM1 (40) .
However, the mechanism of DM1 release remains elusive since the authors were unable to detect co-localization between the internalized T-DM1 and lysosomal LAMP1 by immunofluorescence. Thon and colleagues reported that T-DM1-induced thrombocytopenia occurred via a mechanism that is both HER2 and FcγRIIa independent due to the fact that mouse megakaryocytes and platelets do not express HER2 and FcγRIIa and that both take up T-DM1 (41).
This study suggests that T-DM1 is endocytosed through an alternative pathway (41) . While it is still a matter of debate whether trastuzumab associates with mouse HER2, many laboratories have been using mouse model to investigate the mechanisms of trastuzumab-induced cardiotoxicity, and data from these studies suggest that trastuzumab-induced cardiotoxicity is HER2 dependent (25-29). We used both cellular and mouse model systems to investigate a clinically relevant case of drug-induced hepatotoxicity and to elucidate the possible mechanisms of T-DM1-induced hepatotoxicity. We found that HER2 was expressed in mouse and human hepatocytes, as well as mouse liver and that T-DM1 was able to associate with mouse and human HER2, although binding affinity of trastuzumab or T-DM1 to mouse HER2 is lower than that of human HER2. We also demonstrated that T-DM1 was capable of mediating endocytosis and that the internalized T-DM1 co-localized with lysosomal LAMP1, induced destabilization of 
microtubules and inhibited hepatocyte growth, indicating that DM1 was released in lysosomes and that the released T-DM1 induced cytotoxicity in hepatocytes. According to the public resource of data (www.proteinatlas.org), FcγRIIa, FcγRIIb, FcγRIIIa are not expressed in hepatocytes (42) , suggesting that T-DM1 internalization is unlikely mediated by Fc receptors.
Based on data we have, we propose a novel mechanism by which T-DM1 directly targets hepatocytes via HER2 contributing to T-DM1-induced hepatotoxicity.
Results from our cellular model provide scientific rationale to use mouse as a relevant animal model to further investigate mechanisms of T-DM1-induced hepatotoxicity. Our animal data reveal some important findings. First of all, T-DM1-induced hepatotoxicity is dose dependent. Secondly, trastuzumab was found to induce inflammation, but not necrosis, in liver tissue. Trastuzumab-induced inflammation was recovered within three days, except one mouse in the first cohort (Table 1B) . Thirdly, T-DM1-induced hepatocellular injury contains both inflammation and necrosis (H&E staining) with significant liver function damage, including increase in serum levels of ALT, AST, and LDH. Fourthly, TNFα gene expression in liver tissue is significantly increased in mice treated with T-DM1 as compared with that treated with trastuzumab or vehicle. TNFα is a pro-inflammatory cytokine capable of inducing apoptosis.
Cytokine-mediated pro-apoptotic signaling is an important component in the pathophysiology of drug induced liver injury (43, 44) . It has been reported that TNFα severely enhances liver damage caused by various xenobiotics (43, (45) (46) (47) and is the major cytokine to be excreted by the liver stationary macrophages (Kupffer cells) in response to hepatocyte damage (33) . It is possible that T-DM1-mediated secretion of TNFα, which activates pro-apoptotic signaling pathway, significantly enhances the liver damage that is initially caused by DM1-mediated All groups contained 4 mice tested for H&E staining at each time point, except trastuzumab 72h group in that 3 mice were tested for H&E staining. Table 1 
